Brian R Sloat

Title: Innovations by Brian R Sloat: A Pioneer in Drug Formulations

Introduction

Brian R Sloat, based in Austin, TX, is an accomplished inventor with a focus on pharmaceutical innovations. With a total of four patents to his name, he has made significant contributions to the field of drug formulations, particularly in improving the bioavailability of therapeutic agents. His work addresses critical challenges faced in drug delivery systems.

Latest Patents

Among his latest innovations, Sloat developed a patent for "Precipitation Resistant Small Molecule Drug Formulations." This invention addresses the issue of small molecule drugs, such as diazepam, precipitating at the injection site when delivered as a concentrated formulation. His formulation incorporates at least one surfactant in a non-aqueous environment, which helps prevent precipitation and enhances the drug's absorption into systemic circulation.

Another notable invention is related to "Compositions for the Delivery of Therapeutic Agents and Methods of Use and Making Thereof." This patent focuses on nanoparticle-based compositions aimed at delivering CBD to subjects, with some embodiments showcasing stability for extended periods and improved bioavailability.

Career Highlights

Brian R Sloat has been associated with prominent companies in the pharmaceutical sector, including Xeris Pharmaceuticals, Inc. and Terapio Corporation. His time at these organizations has allowed him to advance his research and push the boundaries of drug formulation technologies.

Collaborations

Throughout his career, Sloat has worked alongside notable colleagues, including Michael A Sandoval and Steven J Prestrelski. These collaborations have fostered a productive environment for innovation and have significantly contributed to the successful development of his patents.

Conclusion

Brian R Sloat's innovative contributions to drug formulation have positioned him as a leading figure in pharmaceutical research. His patents not only tackle pressing issues in drug delivery but also pave the way for more effective therapies. As he continues to explore new avenues in pharmaceutical science, Sloat remains a valuable asset to the industry and the advancement of medical technology.